SCHEMBL18409490

SCHEMBL18409490

Oc1ccccc1N1CCN(Cc2nc(-c3cccc(F)c3)c(-c3cccc(F)c3)[nH]2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 10/20 0.51
GAA P10253 3/20 0.51
ALDH1A1 P00352 2/20 0.51
MAPT P10636 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HTR1A P08908 3/20 0.41
HTR1D P28221 2/20 0.41
HTR2A P28223 2/20 0.41
HTR7 P34969 2/20 0.41
HTR2B P41595 2/20 0.41
HTR6 P50406 2/20 0.41
HTR1B P28222 1/20 0.41
HTR2C P28335 1/20 0.41
DRD2 P14416 3/20 0.40
DRD3 P35462 2/20 0.40
KDM4E B2RXH2 1/20 0.40
POLB P06746 1/20 0.40
HPGD P15428 1/20 0.40
GRIN1 Q05586 1/20 0.39
GRIN2B Q13224 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18409510 0.90 DRD4 (0.47) DRD4GAAALDH1A1MAPTL3MBTL1
SCHEMBL18409305 0.85 DRD4 (0.51) DRD4ALDH1A1MAPTL3MBTL1HTR1A
SCHEMBL18409592 0.84 GAA (0.53) DRD4GAAALDH1A1MAPTL3MBTL1
SCHEMBL18409352 0.84 DRD4 (0.46) DRD4ALDH1A1MAPTHTR1AHTR1D
SCHEMBL18409472 0.84 DRD4 (0.53) DRD4GAAALDH1A1MAPTHTR1A
SCHEMBL18409662 0.83 DRD2 (0.47) DRD4GAAALDH1A1MAPTDRD2
SCHEMBL18409622 0.82 DRD2 (0.51) DRD4GAAALDH1A1L3MBTL1DRD2
SCHEMBL18409737 0.80 DRD4 (0.47) DRD4GAAALDH1A1MAPTL3MBTL1
SCHEMBL18409621 0.79 DRD4 (0.46) DRD4ALDH1A1MAPTHTR1ADRD2
SCHEMBL18409350 0.79 DRD4 (0.48) DRD4ALDH1A1MAPTL3MBTL1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10844051-B2 Substituted oxazoles for the treatment of cancer THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY 2020-11-24 US disclosed
US-20200339554-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2020-10-29 US disclosed
US-20180208586-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2018-07-26 US disclosed
WO-2017011920-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2017-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180208586-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS VHL, TP53, CD44 DRD4 4787/4885GAA 208/4885ALDH1A1 325/4885
US-10844051-B2 Substituted oxazoles for the treatment of cancer OXA1L, PDCD1, MCL1 DRD4 4586/4885GAA 1574/4885ALDH1A1 292/4885
US-20200339554-A1 COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCERS AND OTHER MEDICAL CONDITIONS KRAS, NRAS, VHL DRD4 4249/4885GAA 690/4885ALDH1A1 2287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.